SCHEMBL658139

SCHEMBL658139

CCOC(=O)C(C)Oc1ccc(N)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
KMT2A Q03164 3/20 0.57
CYP1A2 P05177 3/20 0.51
CYP3A4 P08684 2/20 0.51
MAOA P21397 1/20 0.51
EPHX2 P34913 2/20 0.49
MAPT P10636 1/20 0.47
TSHR P16473 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
PPID Q08752 1/20 0.44
ALDH2 P05091 1/20 0.43
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
PDE4D Q08499 1/20 0.42
GAA P10253 3/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829850 0.88 LMNA (0.47) LMNAL3MBTL1KMT2ACYP1A2CYP3A4
SCHEMBL6716380 0.86 L3MBTL1 (0.60) LMNAL3MBTL1KMT2AEPHX2MAPT
SCHEMBL9063261 0.86 LMNA (0.63) LMNAL3MBTL1KMT2ACYP1A2EPHX2
SCHEMBL5205374 0.86 LMNA (0.63) LMNAL3MBTL1KMT2ACYP1A2EPHX2
SCHEMBL9857703 0.86 LMNA (0.63) LMNAL3MBTL1KMT2ACYP1A2EPHX2
SCHEMBL11548487 0.86 L3MBTL1 (0.63) LMNAL3MBTL1KMT2ACYP1A2EPHX2
SCHEMBL18562096 0.86 LMNA (0.63) LMNAL3MBTL1KMT2ACYP1A2EPHX2
SCHEMBL5112826 0.84 LMNA (0.61) LMNAL3MBTL1KMT2AEPHX2MAPT
SCHEMBL7692036 0.84 L3MBTL1 (0.61) LMNAL3MBTL1KMT2ACYP1A2EPHX2
SCHEMBL9621303 0.84 LMNA (0.66) LMNAL3MBTL1KMT2ACYP1A2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4583874-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2025-07-16 EP disclosed
WO-2024132001-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2024-06-27 WO disclosed
WO-2024132001-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2024-06-27 WO disclosed
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses Rigel Pharmceuticals, Inc. (US) 2020-11-10 US disclosed
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2020-07-14 US disclosed
US-10682350-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2020-06-16 US disclosed
US-20200085820-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2020-03-19 US disclosed
US-20190255047-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2019-08-22 US disclosed
US-10369148-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2019-08-06 US disclosed
WO-2003063794-A2 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2003-08-07 WO disclosed
US-5235090-A Synthesis of 2-(4'-aminophenyloxy) alkanoic acids & acids & esters & their derivatives HOECHST CELANESE CORP. (US) 1993-08-10 US disclosed
US-4883901-A Synthesis of 2-(4-aminophenoxy)alkanoic acids and esters and their derivatives HOECHST CELANESE CORPORATION (US) 1989-11-28 US disclosed
EP-0334598-A2 Synthesis of 2-(4'aminophenoxy) alkanoic acids and esters and their derivatives HOECHST CELANESE CORPORATION (US) 1989-09-27 EP disclosed
EP-0107216-B1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND METHOD OF CONTROLLING UNWANTED PLANT GROWTH SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1986-10-01 EP disclosed
US-4452626-A Herbicidal 4-(benzotriazol-1-yl)phenoxy)alkanoic acids, esters and salts SHELL OIL COMPANY (US) 1984-06-05 US disclosed
EP-0107216-A1 Heterocyclic compounds, their preparation, compositions containing them and method of controlling unwanted plant growth SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1984-05-02 EP disclosed
US-4439226-A Herbicidal 4-((benzimidazol-1-yl)phenoxy)alkanoic acids, esters and salts SHELL OIL COMPANY (US) 1984-03-27 US disclosed
US-4358307-A PREFERENTIAL CONTROLLING OF MONOCOTYLEDONS IN CROPS ICI AUSTRALIA LIMITED (AU) 1982-11-09 US disclosed
EP-0026622-A2 Quinoxalinylaminophenoxyalkane carboxylic acid derivatives, their preparation, their use as herbicides and intermediates ICI AUSTRALIA LIMITED (AU) 1981-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200085820-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A LMNA 4827/4885L3MBTL1 4395/4885KMT2A 2984/4885
US-10682350-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A LMNA 4827/4885L3MBTL1 4395/4885KMT2A 2984/4885
US-10709703-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A LMNA 4827/4885L3MBTL1 4395/4885KMT2A 2984/4885
US-10369148-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A LMNA 4827/4885L3MBTL1 4395/4885KMT2A 2984/4885
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A LMNA 4827/4885L3MBTL1 4395/4885KMT2A 2984/4885
US-20190255047-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A LMNA 4827/4885L3MBTL1 4395/4885KMT2A 2984/4885
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A LMNA 4827/4885L3MBTL1 4395/4885KMT2A 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.